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Red man syndrome (RMS) has frequently been reported to occur with intravenous van-
comycin therapy. However, there have been few reports of this complication during
intraperitoneal (IP) treatmentwith vancomycin.This report describes an 11-year-old boywith
end stage renal disease who developed RMS 45min into the initial loading dose of IP van-
comycin for the treatment of bacterial peritonitis with a vancomycin level of 38.8mcg/mL.
The patient developed this adverse reaction despite appropriate initial loading dose per ISPD
guidelines for continuous treatment (1000mg/L). This case emphasizes the importance of
monitoring for adverse reactions of vancomycin therapy, and raises dosing considerations
that differ slightly from the currently recommended ISPD guidelines for IP vancomycin
treatment in the treatment of bacterial peritonitis.
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INTRODUCTION
Bacterial peritonitis is one of the most frequent infectious com-
plications of peritoneal dialysis with significant morbidity. The
current ISPD guidelines for treatment of peritonitis in pediatric
patients recommend intraperitoneal (IP) glycopeptides (either
vancomycin or teicoplanin, which is unavailable in the United
States) for Gram-positive coverage and IP third or fourth gener-
ation cephalosporin for Gram-negative coverage (1). The recom-
mended initial IP vancomycin dose is a 1000 mg/L loading dose
followed by 25 mg/L for maintenance therapy or 30 mg/kg as a
loading dose followed by 15 mg/kg every 3–5 days for intermittent
therapy (1). This loading dose of vancomycin is far higher than
intravenous doses recommended to treat other bacterial infections,
10–15 mg/kg. Potential adverse reactions to vancomycin include
ototoxicity, nephrotoxicity, neutropenia, and phlebitis (2). One
potential adverse reaction of using such a large initial dose of van-
comycin, given all at once, is red man syndrome (RMS). RMS is the
most common toxicity of intravenous vancomycin therapy and is
associated with rapid infusion of large doses of vancomycin (2, 3).
The reaction occurs secondary to histamine release from mast cells
and can manifest as generalized flushing, pruritus, erythematous
rash, chest pain, dyspnea, and hypotension (2, 3). Cardiac toxic-
ity has been reported to be severe enough to cause cardiac arrest
(2). We present the case of an 11-year-old boy who developed
RMS shortly following the initial loading dose of vancomycin for
the treatment of bacterial peritonitis. We also review the litera-
ture that ISPD dosing recommendations for IP vancomycin are
based on and suggest the need for further investigation of dosing
in children, as the currently recommended dose may be too large
for some patients.
CASE REPORT
An 11-year-old 37.3 kg Amish boy with end-stage renal disease
secondary to posterior urethral valves managed with continuous
ambulatory peritoneal dialysis (CAPD) for 2 years presented to the
hospital for the evaluation of peritonitis due to cloudy peritoneal
fluid. His CAPD prescription consisted of four exchanges with a fill
volume of 1400 mL of 1.5% Dianeal. Eight months prior, he had
received 750 mg (20 mg/kg) of IP vancomycin antibiotic prophy-
laxis for a laceration of his PD catheter. Cultures subsequently grew
coagulase-negative Staphylococcus and Enterococcus faecalis, with-
out clinical evidence of peritonitis, which was successfully treated
with 500 mg (13 mg/kg) of intermittent IP vancomycin. He had no
reaction to the IP vancomycin, and he had no previous medication
allergies. On presentation he was well-appearing, afebrile, in no
acute distress, and without abdominal pain or tenderness. The PD
catheter exit site and tunnel were intact. The peritoneal cell count
and differential revealed white blood cell count of 2165/mm3, red
blood cell count of 5/mm3 with a differential of 75% neutrophils,
17% lymphocytes, 6% monocytes, and 2% eosinophils. Peritoneal
fluid cell count and differential were consistent with peritonitis.
Empiric treatment with IP vancomycin and cefepime were ini-
tiated as per ISPD guidelines (1). Vancomycin was administered IP
at a concentration of 1000 mg/L in a 1400 mL long dwell (using the
standard 40 mL/kg dwell volume for a child this age), equivalent
to a total dose of 37.5 mg/kg. Approximately 45 min into the dwell,
the patient developed rash, itching, and agitation consistent with
RMS. The patient was hemodynamically stable. The PD fluid was
drained and the patient was treated with oral Benadryl (25 mg).
The vancomycin level at this time was 38.8 mcg/mL. The patient
clinically improved with Benadryl.
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Ultimately, peritoneal dialysis fluid cultures grew coagulase-
negative Staphylococcus and cefepime treatment was discontin-
ued. The patient was subsequently treated in-house with 30 mg/L
vancomycin to PD and was sent home on day 3 of admis-
sion with intermittent IP vancomycin 350 mg/L or total dose of
15 mg/kg/dose (500 mg) every 3 days for 14 days. Random van-
comycin trough levels were drawn prior to IP vancomycin admin-
istration for close monitoring. Patient had no further episodes of
RMS during vancomycin therapy.
DISCUSSION
In this report, we described a child who developed RMS soon after
the initiation of IP vancomycin as per ISPD guidelines (1). After
a dwell time of only 45 min, the vancomycin level was elevated
at 38.8 mcg/mL. Despite receiving a dose in accordance with the
ISPD guidelines for continuous treatment (1000 mg/L), the total
dose administered (37.5 mg/kg) was in excess of the recommended
loading dose of the ISPD for intermittent therapy (30 mg/kg) (1).
He had not developed RMS when he was treated with IP van-
comycin at a dose between 15 and 20 mg/kg. Upon review of
the literature, there was only one previous report of RMS as a
side effect of IP vancomycin therapy (4). This article, which was
reviewed as part of the ISPD Consensus Guidelines, noted that
the large loading dose of IP vancomycin necessary to obtain ther-
apeutic serum levels is not without risk of side effects. The ISPD
guidelines do not mention RMS as a potential complication (1).
Schaefer et al. performed a controlled, prospective study of IP
antibiotics in treatment of active peritonitis in 152 children and
reported three cases of RMS during the IP vancomycin loading
dose dwell with vancomycin levels as high as 72 mcg/mL (4). The
continuously treated group in this article was treated with a load-
ing dose of only 15 mg/kg IP, a dose well below the 37.5 mg/kg that
our patient received, and adverse effects and elevated vancomycin
levels were still reported (4). This raises the question if the high
loading doses of 1000 mg/L and 30 mg/kg IP is in excess of what
is necessary to achieve an adequate therapeutic vancomycin level,
and if the guidelines should be revised to ensure that the continu-
ous therapy loading dose does not exceed 30 mg/kg? Consideration
should be given to limiting the initial loading dose to 15 mg/kg and
administering an additional 15 mg/kg if there is a subtherapeutic
vancomycin level. The dosing of vancomycin that the ISPD rec-
ommends was determined from extrapolation models from adult
pharmacokinetic studies in patients without active peritonitis that
excluded patients with a history of vancomycin sensitivity (1, 5).
The efficacy of the recommended loading dose has since been
demonstrated in various studies with children but both caution
against the potentially high serum levels of vancomycin (4, 6). Fur-
thermore, Blowey demonstrated marked variability in peritoneal
transport of vancomycin, suggesting that transport status and thus
rapidity of vancomycin uptake varies from patient to patient (6).
Because treatment is continuous and vancomycin transport times
vary, vancomycin blood levels cannot reflect a peak or trough level
of the drug with certainty. Thus, the recommended doses of the
ISPD may not be appropriate for all patients.
Although RMS usually occurs with the first dose of vancomycin,
it can occur at any time even in a patient with previous expo-
sure to the medication (3). This patient had previous tolerated IP
vancomycin well, but at a much lower dose. This is particularly
an issue for patients undergoing PD receiving intermittent ther-
apy with IP vancomycin 30 mg/kg every 5–7 days as an outpatient.
As the goal of the ISPD guidelines is to recommend the therapy
with the highest efficacy and lowest potential for complications,
consideration should be given to specifically mentioning RMS as
a side effect in the next revision of the ISPD guidelines (1). This
would help to guide the physician in advising families what adverse
reactions to watch for at home. It may also be relevant to further
review the literature and include recommendations for prophy-
laxis to avoid the complication of RMS, both in the hospital and
as an outpatient, given the risk for hypotension and potentially
cardiac arrest. Wazny and Daghigh suggest prophylaxis with H1
receptor antagonist (IV diphenhydramine 1 mg/kg, oral hydrox-
yzine 50 mg, oral diphenhydramine 50 mg) to decrease histamine
release and help prevent RMS (3).
Although not available in the United States, teicoplanin is a safer
and equally effective alternative to vancomycin for IP treatment of
Gram-positive organisms in peritonitis. The Schaefer et al. study
mentioned above also compared groups treated with vancomycin
and teicoplanin and documented no hypersensitivity reactions in
the group treated with IP teicoplanin (4). Schaefer’s study also
suggests that teicoplanin, an equally effective glycopeptides, has a
safer overall side effect profile than IP vancomycin. Various other
studies have reported the safety and efficacy of teicoplanin com-
pared to vancomycin (7–9). Thus, teicoplanin may be considered
for use in the future as a safer IP antibiotic to treat Gram-positive
peritonitis or as an option for children with past hypersensitivity
reactions to vancomycin if the drug becomes more widely available
in the United States.
In summary, this report describes a case of RMS developing
following the appropriate initial dose of IP vancomycin for the
treatment of peritonitis in a child. This case demonstrates the
need to closely monitor for side effects of IP vancomycin therapy
and to carefully consider the dosing of IP vancomycin in patients
being treated for bacterial peritonitis. When following the ISPD
guidelines for loading dose of vancomycin for continuous treat-
ment, it is possible to exceed the loading dose recommended for
intermittent therapy if the child’s dwell volume is large because of
patient’s weight. A brief review of the literature also highlights that
vancomycin levels in various studies exceeded those of the patient
described here, even with lower loading doses of vancomycin.
Consideration should be given to lowering the loading dose of
IP vancomycin to avoid side effects and supratherapeutic serum
vancomycin levels.
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